Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the Best Growth Stocks to Buy with the Most Upgrade Potential. Wall Street has a positive view on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), as 71% of the 28 analysts covering the stock have a Buy rating. Additionally, the Street’s average 12-month price target reflects an upside of more than 36.9% from the current level.
On April 1, Barclays analyst Eliana Merle maintained a Buy rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with a price target of $527. The rating comes after the company presented clinical data on its cardiovascular portfolio at the American College of Cardiology’s Annual Scientific Session. At the conference, the company shared results from the HELIOS-B study for Vutrisiran, its ATTR-CM therapy.
Management noted that the analyzes covered improvements in quality of life, subgroup efficacy, and real-world adherence over 613.8 days, with 93.8% of patients remaining on treatment. In a post hoc analysis, 8.0% of vutrisiran patients progressed to advanced disease versus 10.7% of placebo patients during the double-blind phase.
That said, the company posted strong gains in its fiscal fourth quarter 2025 results. It posted revenue of $1.1 billion, a year-over-year increase of 84.95%. EPS for the quarter was $0.82.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is a biopharmaceutical company that develops and commercializes novel therapies based on ribonucleic acid interference.
While we recognize ALNY’s potential as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 7 Big Growth Stocks to Invest in Right Now and 7 Ridiculously Cheap Stocks to Buy According to Wall Street Analysts.
Disclosure: None. Follow Insider Monkey on Google News.